Amylyx Pharmaceuticals (NASDAQ:AMLX) Receives “Buy” Rating from HC Wainwright

Amylyx Pharmaceuticals (NASDAQ:AMLX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 104.08% from the company’s previous close.

Separately, The Goldman Sachs Group increased their price target on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Friday, July 12th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.60.

Amylyx Pharmaceuticals Trading Down 3.9 %

AMLX stock opened at $3.92 on Friday. The company’s 50 day moving average is $2.71 and its 200 day moving average is $2.21. The stock has a market cap of $266.58 million, a price-to-earnings ratio of -3.66 and a beta of -0.55. Amylyx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $19.95.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.35). The company had revenue of ($1.02) million during the quarter, compared to the consensus estimate of $18.83 million. Amylyx Pharmaceuticals had a negative return on equity of 15.51% and a negative net margin of 17.86%. During the same quarter last year, the company posted $0.31 earnings per share. As a group, sell-side analysts forecast that Amylyx Pharmaceuticals will post -2.27 EPS for the current fiscal year.

Insider Activity

In related news, Director George M. Milne, Jr. acquired 100,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was purchased at an average price of $2.20 per share, with a total value of $220,000.00. Following the completion of the purchase, the director now owns 858,571 shares in the company, valued at $1,888,856.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO James M. Frates acquired 40,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was purchased at an average price of $2.53 per share, with a total value of $101,200.00. Following the completion of the purchase, the chief financial officer now owns 233,464 shares in the company, valued at $590,663.92. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director George M. Milne, Jr. acquired 100,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were bought at an average cost of $2.20 per share, with a total value of $220,000.00. Following the purchase, the director now owns 858,571 shares of the company’s stock, valued at approximately $1,888,856.20. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 11.70% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

A number of institutional investors have recently made changes to their positions in AMLX. Goldman Sachs Group Inc. lifted its stake in Amylyx Pharmaceuticals by 5.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,256,861 shares of the company’s stock worth $18,501,000 after acquiring an additional 69,733 shares during the period. Hennion & Walsh Asset Management Inc. lifted its stake in Amylyx Pharmaceuticals by 32.9% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 112,867 shares of the company’s stock worth $321,000 after acquiring an additional 27,937 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Amylyx Pharmaceuticals by 52,575.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock worth $43,000 after acquiring an additional 15,247 shares during the period. Capstone Investment Advisors LLC lifted its stake in Amylyx Pharmaceuticals by 300.4% in the first quarter. Capstone Investment Advisors LLC now owns 80,084 shares of the company’s stock worth $227,000 after acquiring an additional 60,084 shares during the period. Finally, Swiss National Bank lifted its stake in Amylyx Pharmaceuticals by 8.7% in the first quarter. Swiss National Bank now owns 86,600 shares of the company’s stock worth $246,000 after acquiring an additional 6,900 shares during the period. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.